Evidence map›Paper›PMID 33089366›Full record

ArticleAnnals of hematology2021

Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.

Shigeo Fuji, Shuhei Kida, Kayo Nakata, Toshitaka Morishima, Isao Miyashiro, Jun Ishikawa

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shigeo FujiDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan. fujishige1231@gmail.com.ORCID http://orcid.org/0000-0001-5118-7950
Shuhei KidaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Kayo NakataCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Toshitaka MorishimaCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Isao MiyashiroCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Osaka International Cancer Institute · JPOsaka International Cancer Institute · JP

Funding

Health, Labor, and Welfare Sciences Research Grants H30-Gantaisaku-ippan-009Japan Agency for Medical Research and Development 17ck0106342h0001National Cancer Research and Development Fund 29-A-14
6 · The paper itself

Abstract

Peripheral T cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin lymphomas with poor outcomes. Adult T cell leukemia-lymphoma (ATL) and PTCL-not otherwise specified (PTCL-NOS)-are 2 common mature T cell lymphomas in Japan. Since it is unclear whether novel agents and treatment strategies incorporating hematopoietic cell transplantation have contributed to improved clinical outcomes in the real world, we performed a retrospective analysis using data from the population-based Osaka Cancer Registry. From 1977 to 2014, 1274 and 1143 patients were diagnosed with ATL or PTCL-NOS, respectively. Recently, the incidence of both diseases has gradually increased, and the age at diagnosis has risen. The 3-year overall survival (OS) rates in ATL patients were 12.0% in era 1 (1977-1999), 12.4% in era 2 (2000-2008), and 17.5% in era 3 (2009-2014) (P < 0.001). The 3-year OS rates in PTCL-NOS patients were 27.6% in era 1, 36.2% in era 2, and 35.0% in era 3 (P = 0.049). In conclusion, the incidences of ATL and PTCL-NOS have been increasing, particularly in elderly individuals. Clinical outcomes have improved in recent decades but are still unsatisfactory in both diseases. Thus, effective new treatment strategies incorporating novel agents are needed to further improve clinical outcomes in patients with ATL and PTCL-NOS.

Indexed as

Data AnalysisPopulation SurveillanceRegistriesAgedFemaleHumansIncidenceJapanLeukemia-Lymphoma, Adult T-CellLymphoma, T-Cell, PeripheralMaleMiddle AgedRetrospective StudiesSurvival RateAdult T cell leukemia-lymphomaHematopoietic stem cell transplantationPeripheral T cell lymphoma

Identifiers

PMID33089366
OpenAlexW3093553345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.